This study builds upon previous literature surrounding the evaluation of LSD1 inhibitors in various malignancies, including glioblastoma, and expands our past research on LSD1 inhibitors into patient-derived models of glioblastoma (21, 26, 31, 37). Here, KDM1A is linked to glioblastoma.